Supporting Patients When First-Line Therapy Intensifies

Panelists discuss a case-based scenario involving a woman in her late fifties with newly diagnosed epidermal growth factor receptor (EGFR) exon deletion metastatic lung adenocarcinoma, high disease burden, good performance status, and adequate organ function, whose team is intensifying beyond single-agent osimertinib. Drawn to a chemotherapy-free option she read about online, she is anxious about hair loss and nausea while the team weighs osimertinib plus platinum and pemetrexed. Panelists describe acknowledging the emotional shift first, since a patient expecting a pill now faces infusion visits, more frequent laboratory work, and side effects she has preconceived notions about. The discussion covers monitoring counts and renal function, confirming vitamin supplementation with pemetrexed, building a strong antiemetic plan, and preparing her for cumulative fatigue and a predictable post-treatment pattern. Panelists also address transportation, work and caregiving obligations, financial toxicity, and patients arriving informed by online and artificial intelligence sources.